Altered expression of E-cadherin in breast cancer patterns, mechanisms and clinical significance
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsAsgeirsson, K S
Jonasson, J G
Sigurgeirsdottir, J R
Ogmundsdóttir, H M
MetadataShow full item record
CitationEur. J. Cancer. 2000, 36(9):1098-106
AbstractReduced cell adhesion brought about by altered surface expression of E-cadherin has been implicated in invasive and metastatic malignant growth. We investigated the patterns of immunohistochemical E-cadherin expression in 120 breast carcinomas. Furthermore, we analysed DNA from the same samples for loss of heterozygosity (LOH) using three separate microsatellite markers on chromosome 16q22.1. Finally, the clinical outcome was ascertained for 108 patients. 19% (18/97) of infiltrating ductal carcinomas showed complete loss of E-cadherin expression compared with 64% (9/14) of infiltrating lobular carcinomas. LOH was detected in 46% (24/52) of infiltrating ductal carcinomas and 89% (8/9) of infiltrating lobular carcinomas. In the infiltrating lobular carcinomas, LOH was associated with complete loss of cell membrane expression of E-cadherin, although a cytoplasmic expression pattern was evident. In contrast, this association was not seen in the infiltrating ductal carcinomas. In a multivariate analysis, loss of E-cadherin expression was shown to be a significant independent risk factor for a poorer disease-free survival (P=0.019), in particular in the node-negative subset of patients (P=0.029). Significance was also approached for breast cancer corrected survival (P=0.056). We conclude that different mechanisms are involved in the altered E-cadherin expression seen in different subtypes of breast carcinomas. Furthermore, we implicate loss of E-cadherin, regardless of the genetic causes, as an independent prognostic marker for disease recurrence, especially in node-negative breast cancer patients, irrespective of the histological type.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
- Authors: Caldeira JR, Prando EC, Quevedo FC, Neto FA, Rainho CA, Rogatto SR
- Issue date: 2006 Mar 2
- Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast.
- Authors: Palacios J, Sarrió D, García-Macias MC, Bryant B, Sobel ME, Merino MJ
- Issue date: 2003 Jul
- Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features.
- Authors: Palacios J, Benito N, Pizarro A, Suárez A, Espada J, Cano A, Gamallo C
- Issue date: 1995 Mar
- Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
- Authors: Jeschke U, Mylonas I, Shabani N, Kunert-Keil C, Schindlbeck C, Gerber B, Friese K
- Issue date: 2005 May-Jun
- Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence.
- Authors: Jeschke U, Mylonas I, Kuhn C, Shabani N, Kunert-Keil C, Schindlbeck C, Gerber B, Friese K
- Issue date: 2007 Jul-Aug